Discontinuation of Sales of Nefazodone (Serzone)
On 10/02/2003 Bristol-Myers Squibb announced: "It has come to the attention of Health Canada that nefazodone (Serzone) has been associated with adverse hepatic events including liver failure requiring transplantation in Canada. Following discussions with Health Canada, Bristol-Myers Squibb Canada has decided to discontinue sales of nefazodone, effective November 27, 2003.".
|Internet Mental Health © 1995-2011 Phillip W. Long, M.D.|